• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

信号淋巴细胞激活分子家族介导的肿瘤微环境中肿瘤与免疫细胞间的串扰:一种有前景的生物标志物及免疫检查点疗法的潜在治疗靶点

SLAM family-mediated crosstalk between tumor and immune cells in the tumor microenvironment: a promising biomarker and a potential therapeutic target for immune checkpoint therapies.

作者信息

Kwantwi Louis Boafo

机构信息

Department of Anatomy and Neurobiology, College of Medicine, Northeast Ohio Medical University, Rootstown, OH, 44272, USA.

出版信息

Clin Transl Oncol. 2025 Mar;27(3):901-908. doi: 10.1007/s12094-024-03675-2. Epub 2024 Aug 30.

DOI:10.1007/s12094-024-03675-2
PMID:39212911
Abstract

Immune cells infiltrating the tumor microenvironment are physiologically important in controlling cancers. However, emerging studies have shown that cancer cells can evade immune surveillance and establish a balance in which these immune cells support tumor progression and therapeutic resistance. The signaling lymphocytic activation molecule family members have been recognized as mediators of tumor microenvironment interactions, and a promising therapeutic target for cancer immunotherapy. This review is focused on the role of SLAM family in tumor and immune cell interactions and discusses how such crosstalk affects tumor behavior. This will shed insight into the next step toward improving cancer immunotherapy.

摘要

浸润肿瘤微环境的免疫细胞在控制癌症方面具有重要的生理意义。然而,新出现的研究表明,癌细胞能够逃避免疫监视,并建立一种平衡,在这种平衡中,这些免疫细胞会支持肿瘤进展和治疗抵抗。信号淋巴细胞激活分子家族成员已被公认为肿瘤微环境相互作用的介质,也是癌症免疫治疗的一个有前景的治疗靶点。本综述聚焦于信号淋巴细胞激活分子家族在肿瘤与免疫细胞相互作用中的作用,并讨论这种相互作用如何影响肿瘤行为。这将为改进癌症免疫治疗的下一步研究提供思路。

相似文献

1
SLAM family-mediated crosstalk between tumor and immune cells in the tumor microenvironment: a promising biomarker and a potential therapeutic target for immune checkpoint therapies.信号淋巴细胞激活分子家族介导的肿瘤微环境中肿瘤与免疫细胞间的串扰:一种有前景的生物标志物及免疫检查点疗法的潜在治疗靶点
Clin Transl Oncol. 2025 Mar;27(3):901-908. doi: 10.1007/s12094-024-03675-2. Epub 2024 Aug 30.
2
The Emerging Role of CD244 Signaling in Immune Cells of the Tumor Microenvironment.CD244 信号在肿瘤微环境免疫细胞中的新兴作用。
Front Immunol. 2018 Nov 28;9:2809. doi: 10.3389/fimmu.2018.02809. eCollection 2018.
3
Signaling lymphocytic activation molecule family receptors as potential immune therapeutic targets in solid tumors.信号淋巴细胞激活分子家族受体作为实体瘤中潜在的免疫治疗靶点。
Front Immunol. 2024 Feb 27;15:1297473. doi: 10.3389/fimmu.2024.1297473. eCollection 2024.
4
Ferroptosis crosstalk in anti-tumor immunotherapy: molecular mechanisms, tumor microenvironment, application prospects.铁死亡在抗肿瘤免疫治疗中的串扰:分子机制、肿瘤微环境、应用前景。
Apoptosis. 2024 Dec;29(11-12):1914-1943. doi: 10.1007/s10495-024-01997-8. Epub 2024 Jul 15.
5
Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response.树突状细胞、T 细胞炎症肿瘤微环境与免疫治疗反应
Clin Cancer Res. 2020 Aug 1;26(15):3901-3907. doi: 10.1158/1078-0432.CCR-19-1321. Epub 2020 Apr 24.
6
The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.肿瘤微环境对免疫检查点阻断治疗的反应。
Front Immunol. 2020 May 7;11:784. doi: 10.3389/fimmu.2020.00784. eCollection 2020.
7
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.基于免疫检查点抑制剂的癌症免疫治疗耐药性:靶点、生物标志物和治疗方法。
Drug Resist Updat. 2020 Dec;53:100718. doi: 10.1016/j.drup.2020.100718. Epub 2020 Jul 15.
8
Targeting LLT1 as a potential immunotherapy option for cancer patients non-responsive to existing checkpoint therapies in multiple solid tumors.针对在多种实体瘤中对现有检查点疗法无反应的癌症患者,将 LLT1 作为一种潜在的免疫疗法选择。
BMC Cancer. 2024 Nov 7;24(1):1365. doi: 10.1186/s12885-024-13074-z.
9
Tumor Microenvironment Drives the Cross-Talk Between Co-Stimulatory and Inhibitory Molecules in Tumor-Infiltrating Lymphocytes: Implications for Optimizing Immunotherapy Outcomes.肿瘤微环境驱动肿瘤浸润淋巴细胞中共刺激分子与抑制分子之间的相互作用:对优化免疫治疗结果的启示。
Int J Mol Sci. 2024 Nov 29;25(23):12848. doi: 10.3390/ijms252312848.
10
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy.自然杀伤细胞中的免疫检查点分子作为癌症免疫治疗的潜在靶点。
Signal Transduct Target Ther. 2020 Oct 29;5(1):250. doi: 10.1038/s41392-020-00348-8.

引用本文的文献

1
F-FDG PET/CT Predicts the Prognosis of Patients with Hepatocellular Carcinoma Undergoing Liver Transplantation.F-FDG PET/CT预测接受肝移植的肝细胞癌患者的预后。
Liver Cancer. 2025 Mar 5:1-21. doi: 10.1159/000544966.
2
CCL20 in the tumor microenvironment: implications for cancer progression and therapeutic approaches.肿瘤微环境中的CCL20:对癌症进展和治疗方法的影响
Clin Transl Oncol. 2025 Feb 22. doi: 10.1007/s12094-025-03874-5.
3
The Tumor Microenvironment as a Therapeutic Target in Cutaneous T Cell Lymphoma.肿瘤微环境作为皮肤T细胞淋巴瘤的治疗靶点

本文引用的文献

1
The role of signaling lymphocyte activation molecule family receptors in hematologic malignancies.信号淋巴细胞激活分子家族受体在血液系统恶性肿瘤中的作用。
Curr Opin Oncol. 2024 Sep 1;36(5):449-455. doi: 10.1097/CCO.0000000000001067. Epub 2024 Jun 19.
2
A review: Mechanisms and molecular pathways of signaling lymphocytic activation molecule family 3 (SLAMF3) in immune modulation and therapeutic prospects.综述:信号淋巴细胞激活分子家族 3(SLAMF3)在免疫调节中的作用机制及分子途径和治疗前景。
Int Immunopharmacol. 2024 May 30;133:112088. doi: 10.1016/j.intimp.2024.112088. Epub 2024 Apr 15.
3
Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy.
Cancers (Basel). 2024 Oct 1;16(19):3368. doi: 10.3390/cancers16193368.
通过靶向信号淋巴细胞激活分子家族7(SLAMF7)调控的趋化因子配体2(CCL2)信号使免疫抑制性巨噬细胞复极化,可增强肝细胞癌对免疫治疗的敏感性。
Cancer Res. 2024 Jun 4;84(11):1817-1833. doi: 10.1158/0008-5472.CAN-23-3106.
4
Targeted deletion of CD244 on monocytes promotes differentiation into anti-tumorigenic macrophages and potentiates PD-L1 blockade in melanoma.靶向敲除单核细胞上的 CD244 可促进其向抗肿瘤巨噬细胞分化,并增强黑色素瘤中 PD-L1 阻断的效果。
Mol Cancer. 2024 Feb 29;23(1):45. doi: 10.1186/s12943-024-01936-w.
5
TMTC4 is a hair cell-specific human deafness gene.TMTC4 是一个毛细胞特异性的人类耳聋基因。
JCI Insight. 2023 Dec 22;8(24):e172665. doi: 10.1172/jci.insight.172665.
6
Genetic alterations shape innate immune cells to foster immunosuppression and cancer immunotherapy resistance.遗传改变塑造先天免疫细胞以促进免疫抑制和癌症免疫治疗耐药性。
Clin Exp Med. 2023 Dec;23(8):4289-4296. doi: 10.1007/s10238-023-01240-9. Epub 2023 Nov 1.
7
Immunosuppressive CD10ALPL neutrophils promote resistance to anti-PD-1 therapy in HCC by mediating irreversible exhaustion of T cells.免疫抑制性 CD10ALPL 中性粒细胞通过介导 T 细胞不可逆转的耗竭促进 HCC 对抗 PD-1 治疗的耐药性。
J Hepatol. 2023 Dec;79(6):1435-1449. doi: 10.1016/j.jhep.2023.08.024. Epub 2023 Sep 7.
8
Abnormal generation of IL-17A represses tumor infiltration of stem-like exhausted CD8 T cells to demote the antitumor immunity.异常的 IL-17A 生成抑制了具有干细胞样耗竭特征的 CD8 T 细胞向肿瘤的浸润,从而降低了抗肿瘤免疫。
BMC Med. 2023 Aug 21;21(1):315. doi: 10.1186/s12916-023-03026-y.
9
Identification and elucidation of cross talk between SLAM Family Member 7 (SLAMF7) and Toll-like receptor (TLR) pathways in monocytes and macrophages.鉴定和阐明单核细胞和巨噬细胞中信号淋巴细胞激活分子家族成员 7(SLAMF7)和 Toll 样受体(TLR)通路之间的串扰。
Sci Rep. 2023 Jul 7;13(1):11007. doi: 10.1038/s41598-023-37040-0.
10
Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1.重编程免疫抑制性肿瘤微环境可成功清除对放射治疗和抗 PD-1/PD-L1 治疗耐药的肿瘤。
Oncoimmunology. 2023 Jun 15;12(1):2223094. doi: 10.1080/2162402X.2023.2223094. eCollection 2023.